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Purpose: The pathogenesis of lower urinary tract symptoms (LUTS) is uncertain. We 
investigated the potential role of inflammation in the development of LUTS, with the 
use of high-sensitivity C-reactive protein (hsCRP) as an inflammatory marker, in a pop-
ulation-based study of aging men in Korea.
Materials and Methods: Our study used a multistage stratified design to recruit a ran-
dom sample of 1,510 men aged 45 years or older in Chuncheon, Korea, in 2003. Men 
with urologic or neurologic diseases that could cause voiding dysfunction were 
excluded. Also, men with medical conditions that could affect inflammation, such as 
infection or the use of nonsteroidal anti-inflammatory drugs, were excluded. LUTS 
were defined according to the International Prostate Symptom Score (IPSS). Various 
potential confounding factors were included in the analyses.
Results: A total of 330 subjects were included in the final analyses. There were 155 
(47.0%) with an IPSS＜8 and 175 (53%) with an IPSS≥8. The mean age of all subjects 
was 69.2±8.4 years. The mean hsCRP level of all subjects was 2.30±3.27 (median, 1.19) 
mg/l. The hsCRP levels in subjects with an IPSS≥8 differed significantly from those 
in subjects with an IPSS＜8. Also, IPSS, storage symptom, voiding symptom, and qual-
ity of life (QoL) scores increased as hsCRP levels increased, respectively. The hsCRP 
level remained an independent risk factor of LUTS (IPSS≥8, storage symptom score≥
4, incomplete voiding, intermittency, and QoL) after adjustment for variable possible 
confounding factors.
Conclusions: Our results suggest that inflammatory processes may play an important 
role in the pathogenesis of LUTS and that hsCRP levels may indicate the severity of 
LUTS in aging men.
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INTRODUCTION
Lower urinary tract symptoms (LUTS), which are divided 
into storage, voiding, and postvoiding symptoms, can be 
caused by various pathologic conditions. The etiologies of 
LUTS are multiple, and the role of inflammation in the de-
velopment of LUTS has been less well studied [1]. 
Many studies suggest that prostatic inflammation may 
play an important role in histologic benign prostatic hyper-
plasia (BPH) [1-4]. Nevertheless, because LUTS are not 
significantly associated with BPH [5-8] and may develop 
in the absence of histologic BPH, prostatic inflammation 
may not directly affect the development of LUTS. However, 
there still remains a possibility that inflammation in other 
urinary organs, such as the bladder, affects the develop-
ment of LUTS. 
C-reactive protein (CRP) is one of the most extensively 
studied nonspecific markers of systemic inflammation and Korean J Urol 2012;53:335-341
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is a well-established risk factor in coronary events [9]. CRP 
is regarded as a reliable tool for study on inflammation, al-
though the distribution of CRP levels varies among differ-
ent races [10]. Recently, high-sensitivity CRP (hsCRP) was 
introduced, and has more accurate value than conven-
tional CRP in the general population [11].
To the best of our knowledge, there are only four epi-
demiologic studies of inflammation and LUTS with the use 
of CRP as an inflammatory marker [12-15]. Furthermore, 
most of those studies were conducted in the West. Hence, 
we investigated the potential role of inflammation in the 
development of LUTS, by use of hsCRP, in a popula-
tion-based, cross-sectional study of aging men in Korea. 
MATERIALS AND METHODS
1. Study population
In the Hallym Aging Study on the quality of life (QoL) in 
elderly Korean people, a cohort was composed of 2,519 peo-
ple aged 45 years or older who were randomly selected in 
Seoul and Chuncheon, large cities of Korea. Of these, the 
Chuncheon-based cohort was considered in the current 
study. The selection of the study populations can be sum-
marized as follows [16]:
Of the 1,408 study sectors, which were classified on the 
basis of the 2,000 population census, 200 were randomly 
selected. In accordance with the proportion of the pop-
ulation aged 45 years or older from the individual Korean 
neighborhood classifications, the number needed for the 
study population was determined. On the basis of a list of 
study populations that were selected for the current study, 
study participants were systematically sampled. At this 
time, the number of study populations was determined in 
such a manner that 30% of the study population should be 
aged between 45 and 64 years and 70% should be aged 65 
years or older with consideration of the effects of a 
long-term follow-up study as well as the calculation of sta-
ble epidemiological parameters. Of these, 1,510 people who 
responded to the primary panel survey underwent a second 
in-depth study. The survey was completed within a rela-
tively short period, so as to minimize variations in collected 
data. All participants provided written informed consent 
and the study received institutional review board app-
roval.
Of these people, subjects with urologic or neurologic dis-
eases that could cause voiding dysfunction, except for BPH, 
were excluded. Those with medical conditions that could 
affect inflammation, such as infection or the use of non-
steroidal anti-inflammatory drugs, were also excluded. A 
total of 330 male subjects aged 45 years and older were fi-
nally enrolled in the current study.
2. Assessment of LUTS
LUTS were measured by use of the International Prostate 
Symptom Score (IPSS), a clinically validated 7-item 
questionnaire. QoL was also measured. 
The prior 7 items had an ordered answer (from 0 to 5). 
The IPSS was used as both a continuous and a categorical 
variable in 2 groups with no or mild symptoms (IPSS＜8) 
vs. moderate or severe symptoms (IPSS≥8). Using a sim-
ilar approach, the storage symptom and voiding symptom 
scores were used both as continuous and categorical 
variables. The storage and voiding symptom scores were 
categorized into 2 groups as no or mild symptoms (＜4 and 
＜5, respectively) vs. moderate or severe symptoms (≥4 
and ≥5, respectively).
The individual symptom scores were categorized as no 
or mild symptoms (＜3) vs. moderate or severe symptoms 
(≥3). The QoL score concerning the satisfaction of the re-
spondent and had an ordered answer (from 0 to 6) and was 
categorized as ＜4 vs. ≥4.
3. Exposure assessment
 We analyzed age, body mass index (BMI), hypertension, 
diabetes mellitus, dyslipidemia, depression, smoking, al-
cohol drinking, exercise, and hsCRP as variables. All data 
were obtained by trained interviewers or physicians. 
Anthropometric measurements and laboratory tests were 
performed by trained physicians by use of a standardized 
protocol in our institution.
Serum CRP was measured with the hsCRP, fully auto-
mated particle-enhanced nephelometric immunoassay 
(Hitachi 7600 analyzer; Hitachi Ltd, Tokyo, Japan). The 
lower limit of detection was 0.01 mg/l and the interassay 
coefficient of variation was below 5%. 
4. Statistical analysis 
To compare the distributions of variables between no or 
mild symptoms and moderate or severe symptoms, 
Student’s t-test and chi-square test were used in the com-
parison of continuous and categorical variables, respecti-
vely. Simple regression analysis was used to assess the lin-
ear association between hsCRP and LUTS. Then, hsCRP 
levels were categorized as 4 groups according to quartiles. 
Logistic regression models were used to assess the associa-
tion between hsCRP and LUTS and to adjust for potential 
confounding factors. IBM SPSS ver. 18.0 (IBM Co., New 
York, NY, USA) was used for all statistical assessment. All 
p-values were two-sided, and a p＜0.05 was considered sig-
nificant. 
RESULTS
Of the 330 subjects, there were 155 (47.0%) with no or mild 
symptoms and 175 (53%) with moderate or severe symp-
toms. The mean age of all subjects was 69.2±8.4 years. The 
mean serum CRP level of all subjects was 2.30±3.27 mg/l 
(median, 1.19 mg/l). When hsCRP levels were categorized 
according to quartiles, the first, second, third, and fourth 
hsCRP quartiles were ≤0.68 mg/l (Q1), 0.68＜hsCRP≤
1.19 mg/l (Q2), 1.19＜hsCRP≤2.26 mg/l (Q3), and ＞2.26 
mg/l (Q4).
The characteristics of the subjects are shown in Table 1. 
Subjects with moderate or severe symptoms differed sig-Korean J Urol 2012;53:335-341
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TABLE 1. Association of different variables with the severity of LUTS
Variable Total (n=330) IPSS＜8 (n=155) IPSS≥8 (n=175) p-value
Age (yr)
BMI (kg/m
2)
    ≥25
Hypertension
Diabetes mellitus
Dyslipidemia
Depression
Smoking
    Current
    ≥30 packxyear
Alcohol drinking
    Current
    ≥250 ml/wk
Regular exercise
hsCRP (mg/l)
    Q1
    Q2
    Q3
    Q4
69.2±8.4
25.0±2.9
148 (53.4)
  98 (29.7)
  43 (13.0)
26 (7.9)
  7 (2.1)
134 (40.6)
156 (47.3)
203 (62.1)
103 (31.5)
  71 (21.5)
  2.30±3.27
  82 (24.8)
  85 (25.8)
  81 (24.5)
  82 (24.8)
66.7±9.1
25.3±2.7
72 (58.1)
40 (25.8)
16 (10.3)
6 (3.9)
3 (1.9)
51 (32.9)
76 (49.0)
92 (60.1)
38 (24.8)
37 (23.9)
  1.61±1.87
50 (32.3)
42 (27.1)
36 (23.2)
27 (17.4)
71.3±7.1
24.7±3.0
76 (49.7)
58 (33.1)
27 (15.4)
20 (11.4)
4 (2.3)
83 (47.4)
80 (45.7)
111 (63.8)
65 (37.4)
34 (19.4)
2.91±4.04
32 (18.3)
43 (24.6)
45 (25.7)
55 (31.4)
＜0.001
0.091
0.164
0.145
0.169
0.011
1.000
0.007
0.547
0.496
0.015
0.327
＜0.001
0.005
0.616
0.611
0.003
Values are presented as mean±SD or number (%).
LUTS, lower urinary tract symptoms; IPSS, International Prostate Symptom Score; BMI, body mass index; hsCRP, high sensitivity 
c-reactive protein; Q1, first hsCRP quartile (hsCRP≤0.68 mg/l); Q2, second hsCRP quartile (0.68＜hsCRP≤1.19 mg/l); Q3, third hsCRP 
quartile (1.19＜hsCRP≤2.26 mg/l); Q4, fourth hsCRP quartile (hsCRP＞2.26 mg/l).
nificantly from those with no or mild symptoms on several 
parameters. Subjects with moderate or severe symptoms 
tended to be older (p＜0.001), to have more dyslipidemia 
(p=0.011), to have a greater current smoking ratio (p=0.007), 
and to drink more alcohol (p=0.015). The mean hsCRP level 
was higher in persons with moderate or severe symptoms 
than in those with no or mild symptoms (2.91 vs. 1.61 mg/l, 
p＜0.001). When subjects were stratified according to 
quartiles of hsCRP, there were also significant differences 
(18.3% vs. 32.3% in Q1, p=0.005; 31.4% vs. 17.4% in Q4, 
p=0.003).
In linear association model analyses between hsCRP lev-
el and LUTS, IPSS increased as hsCRP levels increased 
(p=0.001) (Fig. 1A). Storage and voiding symptom scores 
and QoL scores also increased as hsCRP levels increased, 
respectively (p=0.003, 0.003, and ＜0.001) (Fig. 1B-D). 
We performed multivariate logistic regression analyses 
that were adjusted for age, BMI, hypertension, diabetes 
mellitus, dyslipidemia, depression, smoking, alcohol 
drinking, and regular exercise. When subjects were strati-
fied according to IPSS≥8 and ＜8, quartiles of hsCRP level 
were an independent risk factor (p=0.020) (Table 2). The 
subjects in Q4 had an OR of 2.856 (p=0.003) (Table 2) com-
pared with those in Q1. Also, when the subjects were strati-
fied according to storage symptom score of ≥4 and ＜4, 
those in Q4 had an OR of 3.344 (p=0.001) (Table 2) com-
pared with those in Q1. However, when the subjects were 
stratified according to voiding symptom score of ≥5 and 
＜5, the hsCRP level did not remain an independent risk 
factor after multivariate adjustment (p=0.084) (Table 2).
In the multivariate logistic analyses of the individual 
symptoms, hsCRP level was an independent risk factor of 
incomplete voiding (p=0.006), intermittency (p=0.043), 
and QoL (p=0.001) (Table 3). The risk of incomplete voiding 
(odds ratio [OR], 3.532; p=0.002), intermittency (OR, 2.437; 
p=0.049), and QoL (OR, 5.203; p＜0.001) increased in Q4 
compared with Q1. 
DISCUSSION
Many studies have suggested that prostatic inflammation 
may have a prominent role in BPH, although the patho-
genesis of BPH is still uncertain [1-4]. Regardless of its 
cause, the end effect of inflammation is an atypical cyto-
kine-rich milieu that can lead to alterations in the micro-
environment and chronic, repetitive wound healing ending 
in the development of BPH nodules [17]. Because most men 
with BPH have LUTS, LUTS and BPH remain intertwined 
in the treatment and study of urinary disorders in aging 
men [18]. Nevertheless, because LUTS are not sig-
nificantly associated with BPH [5-8], inflammation may 
not directly affect the development of LUTS. However, 
there remains a possibility that inflammation affects the 
development of LUTS. It is possible that inflammation in 
the bladder might relate to an effect on bladder function, 
which might result from reduced bladder function, rather 
than increased outlet resistance [19]. This hypothesis is 
supported by investigations including women that had 
suggested a potential role of inflammation in OAB [20-22]. 
Another possibility is that the inflammation might affect Korean J Urol 2012;53:335-341
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FIG. 1. Linear association model analyses between high sensitivity c-reactive protein (hsCRP) level and International Prostate 
Symptoms Scores (A), storage symptom scores (B), voiding symptom scores (C), and quality of life (QoL) scores (D). As hsCRP levels 
increased, the symptoms scores increased.
TABLE 2. Univariate and multivariate logistic regression analyses on predictors of the severity of LUTS
Dependent variable hsCRP
Univariate analysis Multivariate analysis
a
OR 95% CI p-value OR 95% CI p-value
IPSS≥8
Storage SS≥4
Voiding SS≥5
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
1.600
1.953
3.183
2.134
2.834
3.712
2.044
2.061
3.733
0.865-2.958
1.047-3.644
1.679-6.033
1.107-4.115
1.465-5.483
1.918-7.184
0.005
0.134
0.035
＜0.001
0.001
0.024
0.002
＜0.001
0.001
0.024
0.024
＜0.001
1.858
2.156
2.856
2.339
3.128
3.344
1.636
1.707
2.807
0.966-3.576
1.100-4.225
1.445-5.643
1.150-4.760
1.508-6.487
1.638-6.828
0.793-3.375
0.810-3.595
1.281-6.151
0.020
0.064
0.025
0.003
0.004
0.019
0.002
0.001
0.084
0.183
0.159
0.010
LUTS, lower urinary tract symptoms; hsCRP, high sensitivity c-reactive protein; OR, odds ratio; CI, confidence interval; IPSS, 
International Prostate Symptom Score Storage; SS, storage symptom score; Voiding SS, voiding symptom score; Q1, first hsCRP quartile 
(hsCRP≤0.68 mg/l); Q2, second hsCRP quartile (0.68＜hsCRP≤1.19 mg/l); Q3, third hsCRP quartile (1.19＜hsCRP≤2.26 mg/l); Q4, 
fourth hsCRP quartile (hsCRP＞2.26 mg/l).
a: Adjusted for age, body mass index, hypertension, diabetes mellitus, dyslipidemia, depression, smoking, alcohol drinking, and regular
exercise.  Korean J Urol 2012;53:335-341
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TABLE 3. Univariate and multivariate logistic regression analyses on predictors of the individual symptoms of the IPSS
Dependent variable hsCRP 
Univariate analysis Multivariate analysis
a
OR 95% CI p-value OR 95% CI p-value
Question 1≥3 (incomplete voiding)
Question 2≥3 (frequency)
Question 3≥3 (intermittency)
Question 4≥3 (urgency)
Question 5≥3 (weak stream)
Question 6≥3 (straining)
Question 7≥3 (nocturia)
Question 8≥4 (QoL)
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
Q2 vs. Q1
Q3 vs. Q1
Q4 vs. Q1
1.800
3.600
3.940
1.911
2.168
2.255
0.961
2.486
3.356
0.255
0.632
0.955
2.144
2.796
2.852
1.318
2.520
2.640
1.495
1.388
2.255
2.073
2.855
6.218
0.770-4.205
1.607-8.067
1.767-8.781
0.908-4.022
1.031-4.562
1.076-4.725
0.361-2.555
1.049-5.888
1.449-7.775
0.102-0.636
0.304-1.314
0.476-1.916
1.153-3.986
1.482-5.273
1.514-5.372
0.543-3.201
1.102-5.764
1.160-6.008
0.697-3.205
0.637-3.021
1.076-4.725
0.899-4.779
1.259-6.476
2.819-13.717
0.002
0.175
0.002
0.001
0.136
0.088
0.041
0.031
0.004
0.936
0.038
0.005
0.018
0.003
0.219
0.896
0.003
0.016
0.001
0.001
0.045
0.542
0.029
0.021
0.178
0.302
0.409
0.031
＜0.001
0.087
0.012
＜0.001
1.574
3.118
3.532
1.882
2.058
1.690
0.816
2.116
2.437
2.538
3.260
2.887
1.899
2.303
2.126
1.278
2.402
2.024
0.820
0.562
0.784
2.035
2.372
5.203
0.659-3.755
1.365-7.120
1.559-8.002
0.864-4.099
0.935-4.530
0.773-3.696
0.290-2.295
0.844-5.305
1.004-5.917
0.937-6.872
1.213-8.761
1.097-7.600
0.906-3.981
1.067-4.970
0.968-4.671
0.511-3.200
1.001-5.763
0.853-4.805
0.820-4.495
0.562-3.180
0.784-4.032
0.850-4.868
1.004-5.604
2.290-11.823
0.006
0.307
0.007
0.002
0.298
0.111
0.073
0.189
0.043
0.700
0.110
0.049
0.105
0.067
0.019
0.032
0.148
0.089
0.034
0.060
0.166
0.600
0.050
0.110
0.409
0.133
0.512
0.169
0.001
0.111
0.049
＜0.001
IPSS, International Prostate Symptom Score; hsCRP, high sensitivity c-reactive protein; OR, odds ratio; CI, confidence interval; QoL, 
quality of life; Q1, first hsCRP quartile (hsCRP≤0.68 mg/l); Q2, second hsCRP quartile (0.68＜hsCRP≤1.19 mg/l); Q3, third hsCRP 
quartile (1.19＜hsCRP≤2.26 mg/l); Q4, fourth hsCRP quartile (hsCRP＞2.26 mg/l).
a: Adjusted for age, body mass index, hypertension, diabetes mellitus, dyslipidemia, depression, smoking, alcohol drinking, and regular
exercise.  
the neuronal pathways involved in the innervation of the 
urinary tract, which could account for the increased stor-
age voiding symptoms [23].
Our study showed that hsCRP level, a nonspecific in-
flammatory marker, was significantly associated with 
LUTS. The hsCRP levels in subjects with moderate or se-
vere symptoms differed significantly from those in subjects 
with no or mild symptoms. IPSS, storage symptoms, void-
ing symptoms, and QoL scores also increased as hsCRP lev-
els increased, respectively. The hsCRP level remained an 
independent risk factor of LUTS after adjustment for vari-
ous confounding factors.
To the best of our knowledge, there are only four epi-
demiologic studies of inflammation and LUTS that used 
CRP [12-15]. Rohrmann et al. [12] first investigated the as-
sociation between CRP and LUTS by using data from the 
third National Health and Nutrition Examination Survey 
(NHANES III). They did not find a significant association 
between CRP and LUTS. However, the NHANES III study 
had several weak points. Because LUTS were defined as 
only 4 urinary symptoms (incomplete voiding, weak 
stream, hesitancy, and nocturia), the analyses did not re-
flect LUTS exactly. Conventional CRP was also used in-
stead of hsCRP in the analyses. Although conventional 
CRP levels have very high values associated with acute in-
flammation, chronic inflammation can result in near nor-
mal values and can produce clinically meaningless results. 
On the other hand, the clinical utility of the hsCRP level 
is significantly higher than that of conventional CRP in the 
general population, because the hsCRP test can measure 
lower and more exact values compared with the conven-
tional CRP test [9]. In practice, numerous studies have con-Korean J Urol 2012;53:335-341
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sistently shown that hsCRP levels, not conventional CRP 
levels, provide a strong and independent indication of risk 
for cardiovascular diseases [11]. In this point of view, we 
used the complete IPSS including the satisfaction score 
and the hsCRP test measured to two decimal places. 
Two reports were recently published in which CRP levels 
were significantly associated with LUTS in the United 
States [13,14]. One report from the Boston Area Communi-
ty Health survey showed that CRP levels were associated 
with LUTS in men and suggested that the dose-response 
relationship between increased CRP levels and an in-
creased odds of LUTS supported the hypothesized role of 
inflammatory processes in the etiology of LUTS [13]. The 
other report from the Olmsted County study showed that 
CRP levels were not associated with change in prostate vol-
ume but were associated with rapid increases in irritative 
LUTS, suggesting that inflammatory processes may play 
a role in the development of these outcomes [14]. The re-
sults from the above 2 studies were very similar to our 
results. Our study demonstrated that the IPSS, storage 
symptom scores, voiding symptom scores, and QoL scores 
increased as hsCRP levels increased, respectively. The 
hsCRP levels were also significantly associated with over-
all LUTS and storage symptoms after adjustment for vari-
ous potential confounding factors. Note that those 2 studies 
were performed in the West. Several studies have sug-
gested that significant race and gender differences exist in 
the population distribution of CRP levels [10,24]. In this re-
spect, our study showed that CRP levels were significantly 
associated with LUTS, which suggests that inflammatory 
processes may play a role in the pathogenesis of LUTS in 
Korea as well as in westerners. Accordingly, our study is 
worthy of notice because it is the first such investigation 
in Korea. 
More recently, Lu et al. [15] published a study to inves-
tigate the correlation between hsCRP levels and LUTS by 
using data from the Fangchenggang Area Male Health and 
Examination Survey (FAMHES) in China. They found that 
hsCRP levels were associated with overall LUTS, irritative 
symptoms, urgency, and nocturia, suggesting a positive 
correlation of hsCRP with LUTS. The results from the 
FAMHES study were also similar to those of our study. 
However, it should be noted that there was a distinct differ-
ence in age distribution between our study (mean, 69.2±8.4 
years) and the FAMHES study (mean, 36.6±10.7 years), 
because age is one of the most well-known risk factors in 
the development of LUTS. Despite the difference in age dis-
tribution, hsCRP levels were still significantly associated 
with LUTS, which suggests that inflammatory processes 
may play a role in the pathogenesis of LUTS in aging men.
In our study, it was interesting that hsCRP levels were 
significantly associated with storage symptoms, not void-
ing symptoms, because LUTS in aging men are generally 
most likely related to BPH and present as voiding symp-
toms. Our results do not discount the possibility that pro-
static inflammation is associated with histologic BPH. 
However, because LUTS are not significantly associated 
with BPH [5-8] and may develop in the absence of histologic 
BPH, our results suggest that the inflammatory process in 
LUTS might be more related to an effect on bladder func-
tion than on the prostate.
From the viewpoint of individual LUTS, hsCRP levels 
were significantly associated with incomplete voiding, in-
termittency, and QoL in our study. We first demonstrated 
the significant association between hsCRP levels and QoL. 
Because LUTS represent a cluster of chronic urinary dis-
orders without identification of organ-specific or dis-
ease-specific causes, it is important for the diagnosis and 
treatment of LUTS that the degree of subjective QoL be de-
fined, as well as the severity of LUTS. It may be a clue to 
the availability of the hsCRP test in real practice.
The results for individual symptoms in previous studies 
including our study were slightly different. Although the 
exact reasons for these differences are unclear, several ex-
planations are possible. First, previous studies including 
our study did not determine all possible risk factors for 
LUTS. Also, the distribution of hsCRP levels varies among 
different races [10,24]. Also, because the categorical range 
of individual symptom scores (0 to 5) is relatively smaller 
than that of the overall IPSS (0 to 35), storage symptom 
score (0 to 15), and voiding symptom score (0 to 20), in-
dividual symptoms could be easily influenced by confound-
ing factors. 
There were a few limitations to our study. First, our study 
was limited geographically to the local area and had a rela-
tively small population. However, our study had a systemi-
cally randomized multistage stratified design to reduce the 
bias. Second, our study did not determine all possible risk 
factors for LUTS. However, analyses from our study con-
sidered similar or more confounding factors than in pre-
vious studies. Finally, because our study was cross-sec-
tional in design, we could not confirm whether in-
flammation was a risk factor for LUTS or not.
CONCLUSIONS
Our study demonstrated that hsCRP levels were sig-
nificantly associated with overall LUTS, storage symp-
toms, incomplete voiding, intermittency, and QoL. Our re-
sults suggest that the inflammatory process may play an 
important role in the pathogenesis of LUTS and that 
hsCRP levels may indicate the severity of LUTS in aging 
men. 
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